Apr 6, 2020Global Plasma Leaders Collaborate to Accelerate Development of Potential COVID-19 Hyperimmune TherapyPartnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19
Osaka, JAPAN, and King of Prussia, PA, USA 06 Apr 2020 Biotest, BPL, LFB, and Octapharma have joined an alliance formed by CSL Behring (ASX:CSL/USOTC:CSLLY) and Takeda Pharmaceutical Company...
Feb 13, 2020University City Science Center partnership with CSL Behring accelerates the search for new biotherapies at the University of Pittsburgh and the University of DelawareUniversities awarded $250,000 research grants as part of the CSL Behring-Science Center Research Acceleration Initiative
Universities awarded $250,000 research grants as part of the CSL Behring-Science Center Research Acceleration Initiative 13 Feb 2020 PHILADELPHIA – February 13, 2020 – Researchers at the...
Feb 11, 2020PRIVIGEN® (Immune Globulin Intravenous (Human), 10% Liquid) Granted Orphan-Drug Designation for the Investigational Treatment of Systemic Sclerosis (SSc)CSL Behring advances Ig clinical trial program to address unmet need in treating serious autoimmune disease
KING OF PRUSSIA, Pa.– February 11, 2020 – Global biotherapeutics leader CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted Privigen® (Immune Globulin...
Jan 21, 2020This year’s rankings based on independent survey of more than 60,000 U.S. employees across industries
KING OF PRUSSIA, Pa., 21 January 2020 – Forbes Magazine today named CSL Behring among its Best Employers for Diversity 2020. The annual rankings, which measure diversity across six different...
Jan 10, 2020
Melbourne, Australia 10 Jan 2020 Melbourne researchers have determined the molecular basis for how an important component of the immune system, called gamma-delta T cells, detects infections and...